|
|
|
|
| LEADER |
01707 am a22002413u 4500 |
| 001 |
106836 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Stokes, CL
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
| 100 |
1 |
0 |
|a Lauffenburger, Douglas A
|e contributor
|
| 100 |
1 |
0 |
|a Cirit, Murat
|e contributor
|
| 700 |
1 |
0 |
|a Lauffenburger, Douglas A
|e author
|
| 700 |
1 |
0 |
|a Cirit, Murat
|e author
|
| 245 |
0 |
0 |
|a Physiome-on-a-Chip: The Challenge of "Scaling" in Design, Operation, and Translation of Microphysiological Systems
|
| 260 |
|
|
|b Nature Publishing Group,
|c 2017-02-02T21:00:09Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/106836
|
| 520 |
|
|
|a Scaling of a microphysiological system (MPS) or physiome-on-a-chip is arguably two interrelated, modeling-based activities: on-platform scaling and in vitro-in vivo translation. This dual approach reduces the need to perfectly rescale and mimic in vivo physiology, an aspiration that is both extremely challenging and not substantively meaningful because of uncertain relevance of any specific physiological condition. Accordingly, this perspective offers a tractable approach for designing interacting MPSs and relating in vitro results to analogous context in vivo.
|
| 520 |
|
|
|a United States. Defense Advanced Research Projects Agency. Microphysiological Systems Program (Grant W911NF-12-2-0039)
|
| 520 |
|
|
|a National Institutes of Health (U.S.) Microphysiological Systems Program (Grant 4-UH3-TR000496-03)
|
| 520 |
|
|
|a United States. Army Research Office (Institute for Collaborative Biotechnologies. Grant W911NF-09- 0001)
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t CPT: Pharmacometrics & Systems Pharmacology
|
